Eli Lilly's weight loss drugs, especially Zepbound and Mounjaro, have driven impressive revenue growth. Click here to read an ...

A new scientific study has found that weight loss jabs such as Mounjaro and Ozempic can help protect against serious health issues like dementia ...

Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three ...

Eli Lilly and Company’s LLY stock has declined 15.7% in the past year. The first-quarter earnings miss, guidance cut and some ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from ...

While Mounjaro has no doubt been a monumental success, Lilly was also working on something else in the background. As Novo Nordisk did, Lilly developed an alternative version of its diabetes drug ...

Lilly rides Mounjaro, Zepbound to better-than-expected 1Q profit despite supply issues A sign for Eli Lilly & Co. sits outside their corporate headquarters in Indianapolis on April 26, 2017.